Nanobiotix

NBTX · Nasdaq · France

Share price · NBTX

$26.90-14.18 (-34.52%) 3M

close as of 2026-11-18 · 24h delayed · vol 44K (0.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when NBTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 22 Oct 2026+13.0%
  2. 20 Oct 2026+14.5%
  3. 1 Oct 2026-10.5%
  4. 24 Aug 2026-8.9%
  5. 17 Aug 2026+9.8%

    Nothing announced by NBTX that day or the session before.

  6. 11 May 2026+17.7%
  7. 6 May 2026+20.4%
  8. 4 May 2026-11.3%
  9. 11 Mar 2026-14.0%

    Nothing announced by NBTX that day or the session before.

  10. 9 Mar 2026+18.1%

Share of unusual movement by asset

For each asset, the share of NBTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
NBTXR3
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—29%
Sessions with no dated event—71%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
Hafnium-oxide nanoparticle radioenhancerOther
Non-Small Cell Lung CancerHead and Neck Squamous Cell Carcinoma

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
June 2028 (1)
NBTXR3Phase 3Carcinoma, Squamous Cell
Est. primary completion 2028-06-30 · NCT04892173 · CT.gov ↗
What to watch
December 2028 (1)
NBTXR3Phase 2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2028-12-31 · NCT06667908 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$37M$26M$62M$6.8M-$38M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY-$7.8M$44M$52M$18M-$21M operating cash flowreport ↗
2023-FY$39M$42M$83M$11M-$14M operating cash flowreport ↗
2022-FY$5.0M$34M$44M$15M-$39M operating cash flowreport ↗
2021-FY$3.1M$36M$95M$14M-$35M operating cash flowreport ↗

Insider transactions

This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 15 reporting institutions held 5.7M shares ($175.9M).

#InstitutionSharesValue
1JOHNSON & JOHNSON5,623,816$173.6M
2MORGAN STANLEY36,274$1.1M
3Optiver Holding B.V.13,501$417K
4MARSHALL WACE, LLP9,239$285K
5UBS Group AG5,557$172K
6BNP PARIBAS FINANCIAL MARKETS3,559$110K
7RHUMBLINE ADVISERS2,281$70K
8ROYAL BANK OF CANADA1,825$56K
9GAMMA Investing LLC828$26K
10EverSource Wealth Advisors, LLC514$16K
11OSAIC HOLDINGS, INC.500$15K
12WELLS FARGO & COMPANY/MN200$6K
13NATIONAL BANK OF CANADA /FI/13$394
14Tower Research Capital LLC (TRC)1$31
15CITIGROUP INC1$31